MENU
CVM
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION

CVM stock forecast, quote, news & analysis

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 06, 2026

Why CEL-SCI Corporation (CVM) Stock Is Down -35.7% in the Last 30 Days

Key Takeaways

  • CEL-SCI Corporation (CVM) shares fell about 35.7% over the last 30 days, from a closing price of $2.13 on October 7, 2026, to $1.37 on November 5, 2026.
  • The decline reverses a sharp early-October rally that peaked near $2.74, as speculative momentum around Phase 3 Multikine data unwound.
  • As a pre-revenue, clinical-stage biotechnology company, CEL-SCI's share price is driven primarily by clinical data, regulatory milestones, and financing news rather than current fundamentals.
  • Over the trailing three months, the stock is lower by roughly 15%, reflecting a volatile round-trip rather than a sustained trend.
  • Key catalysts ahead include the 212-patient FDA confirmatory registration study for Multikine and the Saudi Arabia commercialization track with Amarox.
  • For additional detail on valuation and expectations, explore CEL-SCI's Price Targets, Earnings, and Forecast pages.
  • Traders can also explore Trending AI Robots to see how AI trading bots are positioning across thousands of tickers.

CEL-SCI Corporation (CVM) Company Overview and Market Position

CEL-SCI Corporation is a clinical-stage biotechnology company headquartered in Vienna, Virginia, focused on immunotherapy treatments for cancer and infectious diseases. Its lead product candidate is Multikine (Leukocyte Interleukin, Injection), an investigational neoadjuvant immunotherapy administered before surgery to newly diagnosed patients with locally advanced head and neck cancer. The company is also developing its Ligand Epitope Antigen Presentation System (LEAPS) platform. CEL-SCI's completed Phase 3 study of Multikine showed a 73% five-year survival rate in a biomarker-selected population versus 45% for standard of care alone. Investors follow the stock for the progress of its 212-patient FDA confirmatory registration study, its partnership with Saudi Arabia-based Amarox for potential commercialization, and the company's financing activity as a pre-revenue enterprise.

CEL-SCI Corporation (CVM) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CVM shares declined approximately 35.7%, falling from a closing price of $2.13 on October 7, 2026, to $1.37 on November 5, 2026. The move was concentrated in the second half of October, when the stock gave back the entirety of its early-month rally and then extended lower into early November.

The quarterly picture is more nuanced. Measured over the trailing three months, the stock is down roughly 15%, from about $1.61 in early August to $1.37. That net decline, however, conceals significant intra-quarter volatility: shares climbed steadily through September, peaked near $2.74 on October 6, and then reversed sharply. The result is a round-trip price pattern characteristic of a thinly traded, catalyst-driven small-cap biotechnology name.

What Drove CVM Stock Price in the Last 30 Days

The last 30 days were defined more by the reversal of a rally than by a single negative development. Through late September and the first week of October, CVM shares climbed as investors anticipated and digested new Phase 3 Multikine data, including biomarker analyses showing a 73% five-year survival rate in the target patient population. The stock peaked near $2.74 on October 6.

From that point, the shares unwound steadily. On October 26, CEL-SCI presented additional Phase 3 data at a World Congress, but by then the move had already largely reversed, reflecting a classic pattern of profit-taking after a sharp, news-driven run-up. Because CEL-SCI generates no product revenue, its valuation is sensitive to financing risk; the company completed multiple stock offerings earlier in 2026, and the resulting dilution overhang weighs on sentiment whenever shares advance. There was no single company-specific negative announcement during the period, but the combination of fading momentum, persistent capital needs, and broad pressure on speculative small-cap biotech contributed to the decline.

What Drove CVM Stock Performance Over the Last Quarter

The broader three-month trend was shaped by a sequence of clinical, regulatory, and financing milestones. In July, CEL-SCI launched its global 212-patient FDA confirmatory registration study for Multikine in newly diagnosed head and neck cancer, and in August it reported fiscal third-quarter results showing a narrower net loss per share versus the prior year. A peer-reviewed publication in Oral Oncology supporting Multikine's biomarker strategy and the October World Congress presentation reinforced the clinical narrative and helped drive the early-quarter rally.

At the same time, the company's financing activity remained a central theme. Offerings earlier in 2026 raised roughly $7.2 million in May and $2.5 million in June, with additional proceeds reported during the fiscal third quarter. Insider filings also showed the chief executive officer purchasing shares in August, while management received equity grants at $2.06 per share in late September. The interplay between positive clinical momentum and ongoing dilution risk produced the stock's volatile, two-sided quarterly performance.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots drawn from a broader platform of hundreds of bots that trade thousands of tickers. Rather than listing every strategy, the section highlights only the top-performing and most relevant bots, helping traders quickly identify systems that are currently standing out. The bots vary considerably in strategy, holding timeframe, and performance metrics, so no single approach fits every trader or market condition. For those interested in applying systematic, data-driven methods to names like CVM, exploring the Trending AI Robots page can offer a useful starting point.

CVM Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the most important variable is enrollment progress in the 212-patient FDA confirmatory registration study, along with any early pre-surgical tumor response data that could support a potential accelerated-approval pathway. In parallel, investors are monitoring the Saudi Arabia track, where a Breakthrough Medicine Designation application through partner Amarox could create a path to near-term commercialization and revenue. CEL-SCI's next quarterly earnings report, expected in November 2026, will provide updates on cash position, spending, and trial execution. Financing and dilution remain key risks, given the company's pre-revenue status and limited cash runway. Broader sentiment toward small-cap biotechnology and the biotech financing environment will also continue to influence trading. Analysts tracked by major data providers currently hold a Buy consensus with a 12-month price target near $12.50, though estimates vary widely given the early stage of the business.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for CVM with price predictions
Nov 18, 2026

Momentum Indicator for CVM turns positive, indicating new upward trend

CVM saw its Momentum Indicator move above the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In 85 of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CVM's RSI Oscillator exited the oversold zone, 29 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 64 of 77 cases where CVM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for CVM just turned positive on November 16, 2026. Looking at past instances where CVM's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.

Following a +44.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVM advanced for three days, in 182 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

CVM moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CVM crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CVM broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CVM entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. CVM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.328) is normal, around the industry mean (3.592). P/E Ratio (-0.858) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of immunotherapy products for the treatment of cancer and infectious diseases

Industry Biotechnology

Industry
Biotechnology
Address
8229 Boone Boulevard
Phone
+1 703 506-9460
Employees
57
Web
https://www.cel-sci.com
Why CEL-SCI Corporation (CVM) Stock Is Down -35.7% in the Last 30 Days